Note: Biopta (Glasgow, UK and Maryland, USA) is now REPROCELL’s Center for predictive Drug Discovery.
Note: Reinnervate (Durham, UK) is now part of REPROCELL’s Center for predictive Drug Discovery.
On the REPROCELL blog
Latest
.jpg?width=1000&height=562&name=blog%20images%20(1).jpg)
How Human Tissue Testing Adds Commercial Value for Shareholders
Discover how human tissue testing enhances shareholder value, exploring its impact on drug discovery, precision medicine, and regenerative medicine within the life sciences industry.
03 September 2025
Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025
Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.
02 September 2025
NIH Announces End to Exclusive Funding for Animal Model Research
NIH ends exclusive funding for animal model research, promoting New Approach Methodologies like organ-on-a-chip systems and human tissue testing.
18 August 2025
Revolutionizing IBD Research with Innovative In Vitro Models
Catch a glimpse into the future of inflammatory bowel disease (IBD) research with our ground breaking in vitro models.
11 August 2025
.jpg?width=800&height=450&name=Biopta%20(Scottish%20Life%20Sciences).jpg)
